DOCK 1: Mitral Valve Replacement With MValve Dock and Lotus
Study Details
Study Description
Brief Summary
This study evaluates the MValve mitral prosthesis in conjunction with a Lotus transcatheter heart valve (THV) for mitral valve replacement in subjects at high risk for conventional mitral valve replacement or repair surgery.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This study is a prospective first in man feasibility study intended to evaluate preliminary safety and effectiveness of the MValve Mitral Dock with Lotus transcatheter heart valve for mitral valve replacement in subjects who are at high risk for surgical valve repair or replacement.
The surgical technique adapts the valve-in-valve approach for mitral replacement in degenerated mitral prostheses to failing native mitral valves. The MValve Dock is designed to provide a structural platform within the mitral annulus so that the Lotus THV can be implanted in a secure fashion in the mitral annulus. The investigational device anchors to the mitral annulus commissures, sparing the native valve leaflets and sub annular apparatus. This study is designed to treat subjects with moderate-to-severe MR who are not deemed candidates for mitral valve surgery.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Valve Replacement Mitral valve replacement |
Device: mitral valve replacement
transcatheter mitral valve replacement
|
Outcome Measures
Primary Outcome Measures
- Composite serious adverse cardiac events and stroke [30 days]
death, myocardial infarction, stroke, repeat surgery
Secondary Outcome Measures
- Mitral regurgitation grade [1 year]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Symptomatic ≥3+ degenerative or functional mitral regurgitation of either ischemic or non-ischemic etiology based by a qualifying echocardiography obtained within 90 days prior to the procedure.
-
New York Heart Association (NYHA) Functional Class III or IV.
-
High risk for conventional open mitral valve repair or replacement surgery in the consideration of the site Heart Team.
-
Left Ventricular Ejection Fraction (LVEF) is ≥30% within 30 days prior to the procedure.
-
Mitral valve annular commissure to commissure (C/C) dimension between 30-35 mm by echocardiography.
-
Left atrial diameter <5.5 cm by echocardiography
Exclusion Criteria:
-
Prior mitral valve replacement or repair surgery.
-
Prior transapical surgery.
-
Severe aortic or tricuspid valve disease. - Severe symptomatic carotid stenosis (>70% by ultrasound).
-
ACC/AHA Stage D heart failure.
-
Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology.
-
Infiltrative cardiomyopathies (amyloidosis, hemochromatosis, sarcoidosis).
-
Physical evidence of right-sided congestive heart failure with echocardiographic evidence of moderate or severe right ventricular dysfunction.
-
Severe mitral annular calcification.
-
Glomerular filtration rate (GFR) < 30.
-
Hemodynamic instability defined as systolic pressure < 90 mm Hg with or without afterload reduction, cardiogenic shock, or the need for inotropic support or intra-aortic balloon pump or other hemodynamic support device, or any mechanical heart assistance.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Dante Pazzenese Institute of Cardiology | Sau Paulo | Brazil | ||
| 2 | Clinique Pasteur | Toulouse | France | ||
| 3 | University of Bonn - Medizinische Klinik und Poliklinik II | Bonn | Germany | ||
| 4 | University of Poznan | Poznan | Poland |
Sponsors and Collaborators
- MValve Technologies Ltd
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CIP 01-2015